B2M and cancer: The downregulation of MHC-I and B2M diminished immunogenicity in high-grade OS, which may be a potential mechanism for cancer immunotherapy resistance. In addition, CD24, a novel “don’t eat me” signal, also facilitated immune evasion of osteosarcoma cells.